A RANDOMIZED, PHASE II STUDY COMPARING TRASTUZUMAB AND VINORELBINE IN COMBINATION WITH AVELUMAB OR AVELUMAB AND UTOMILUMAB (41BB/CD137 AGONIST), IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON PRIOR TRASTUZUMAB AND PERTUZUMAB: The "AVIATOR" Study

Study Overview

To determine whether the addition of avelumab to the combination of trastuzumab and vinorelbine will improve progression-free survival (PFS) compared to the trastuzumab and vinorelbine combination alone in patients with advanced HER2-positive breast cancer.

To determine whether the addition of utomilumab to the combination of avelumab, trastuzumab, and vinorelbine will improve progression-free survival (PFS) compared to the avelumab, trastuzumab, and vinorelbine combination alone in patients with advanced HER2-positive breast cancer.

 

• IRB Number: 1808735796
• Research Study Identifier: TX10561
• Principal Investigator: Anna Maria Storniolo, MD